-
Archives
- June 2018
- February 2018
- May 2017
- January 2017
- December 2016
- November 2016
- October 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- August 2015
- July 2015
- June 2015
- March 2015
- February 2015
- September 2014
- July 2014
- January 2014
- November 2013
- July 2013
- June 2013
- April 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- June 2012
- May 2012
- March 2012
- December 2011
- November 2011
- July 2011
- March 2011
-
Meta
Tag Archives: Club Phase 1
Exploratory medicines development – Innovation and risk management
First EUFEMED Conference Joint Meeting of European Human Pharmacological Societies Wednesday 17 May – Friday 19 May, 2017, London/UK Assessment and mitigation of risk are most challenging in exploratory drug development when a promising new compound is to be characterised … Continue reading
Comments Off on Exploratory medicines development – Innovation and risk management
Club Phase 1 meeting, Paris
Club Phase 1, a group representing early clinical development stakeholders in France, held their 16th Annual Meeting in Paris on 22nd March. Topics ranged from dealing with immunogenicity to Drug Drug Interactions and a session led by a Biotrial representative … Continue reading
Comments Off on Club Phase 1 meeting, Paris
Club Phase 1 to hold it’s next meeting in Paris on 22-Mar-2016
Club Phase 1, the AHPPI’s French sister human pharmacology organisation, will be holding it’s next meeting in Paris on 22 March. The draft outline of the programme is included below: Regulatory– Update on early phase clinical trial approval & on … Continue reading
Comments Off on Club Phase 1 to hold it’s next meeting in Paris on 22-Mar-2016
Statement on the Recent Serious Adverse Events During a Clinical Trial in Europe
The European Federation for Exploratory Medicines Development (EUFEMED) yesterday posted a statement about the widely reported death and serious illnesses occurring in an exploratory clinical trial in Europe (link PRNewswire). EUFEMED is headquartered in Brussels and constitutes the federated member associations of … Continue reading
Comments Off on Statement on the Recent Serious Adverse Events During a Clinical Trial in Europe
Club Phase 1 invite AHPPI members to 4th February meeting
Predictive Toxicology and Clinical Pharmacology, Paris (France), 4th February 2014 Our colleagues at Club Phase 1 invite AHPPI members to their upcoming annual meeting. Interested parties should register no later than 25th January 2014. Further details can be found here. … Continue reading
Comments Off on Club Phase 1 invite AHPPI members to 4th February meeting
Message from Chair: Presentations from the Joint Conference of European Human Pharmacological Societies
Dear Members, I have recently returned from a very successful and interesting International meeting in France held between the French (Club Phase 1), German (AGAH), Belgian (BAPU) and UK (AHPPI),human pharmacological societies. The meeting was entitled EARLY CLINICAL UTILITY ASSESSMENT … Continue reading